Immune response to intravenous immunoglobulin in patients with Kawasaki disease and MIS-C

Zhu, Yanfang P; Shamie, Isaac; Lee, Jamie C; Nowell, Cameron J; Peng, Weiqi; Angulo, Shiela; Le, Linh Nn; Liu, Yushan; Miao, Huilai; Xiong, Hainan; Pena, Cathleen J; Moreno, Elizabeth; Griffis, Eric; Labou, Stephanie G; Franco, Alessandra; Broderick, Lori; Hoffman, Hal M; Shimizu, Chisato; Lewis, Nathan E; Kanegaye, John T; Tremoulet, Adriana H; Burns, Jane C; Croker, Ben A

BACKGROUNDMultisystem inflammatory syndrome in children (MIS-C) is a rare but potentially severe illness that follows exposure to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Kawasaki disease (KD) shares several clinical features with MIS-C, which prompted the use of intravenous immunoglobulin (IVIG), a mainstay therapy for KD. Both diseases share a robust activation of the innate immune system, including the IL-1 signaling pathway, and IL-1 blockade has been used for the treatment of both MIS-C and KD. The mechanism of action of IVIG in these 2 diseases and the cellular source of IL-1ß have not been defined.METHODSThe effects of IVIG on peripheral blood leukocyte populations from patients with MIS-C and KD were examined using flow cytometry and mass cytometry (CyTOF) and live-cell imaging.RESULTSCirculating neutrophils were highly activated in patients with KD and MIS-C and were a major source of IL-1ß. Following IVIG treatment, activated IL-1ß+ neutrophils were reduced in the circulation. In vitro, IVIG was a potent activator of neutrophil cell death via PI3K and NADPH oxidase, but independently of caspase activation.CONCLUSIONSActivated neutrophils expressing IL-1ß can be targeted by IVIG, supporting its use in both KD and MIS-C to ameliorate inflammation.FUNDINGPatient Centered Outcomes Research Institute; NIH; American Asthma Foundation; American Heart Association; Novo Nordisk Foundation; NIGMS; American Academy of Allergy, Asthma and Immunology Foundation.